Kritische 8-K Meldungen
| Datum | Meldung | Schwere | Filing | Auszug |
|---|---|---|---|---|
| 21.05.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | hange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain O |
| 13.11.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | orth by specific reference in such filing. Item 5.02 Departure of Directors or Certain Officers; Election of Directors |
| 06.10.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | (a) of the Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Appointment of Certain Officers |
| 15.08.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | (a) of the Exchange Act. ☐ Item 5.02 Departure of Director or Certain Officers; Election of Directors; Appointme |
| 12.06.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | ir entirety by reference to such exhibits. Item 5.02. Departure of Directors or Principal Officers; Election of Direct |
| 21.02.2023 | Item 4.02 — Bilanzkorrekturen | EXTREM | SEC | Item 4.02. Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Inter |
| 14.02.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; |
Stammdaten
Aytu Biopharma, Inc., a specialty pharmaceutical company, focuses on developing and commercializing novel therapeutics and consumer healthcare products the United States and internationally. The company offers Adzenys XR-ODT for the treatment of attention deficit hyperactivity disorder (ADHD) in patients from 6 years and older; Cotempla XR-ODT for the treatment of ADHD in patients from 6 to 17 years old; and Adzenys ER, an oral suspension for the treatment of ADHD in patients from 6 years and older. It also provides Karbinal ER, a carbinoxamine oral suspension for the treatment of seasonal and perennial allergies; Poly-Vi-Flor and Tri-Vi-Flor prescription supplements for infants and children for the treatment of fluoride deficiency; Tuzistra XR, a prescription antitussive consisting of codeine polistirex and chlorpheniramine polistirex in an oral suspension; and ZolpiMist, an oral spray for the treatment of insomnia. The company was formerly known as Aytu BioScience, Inc. and changed its name to Aytu Biopharma, Inc. in March 2021. Aytu Biopharma, Inc. was incorporated in 2015 and is headquartered in Englewood, Colorado.
Unternehmen & Branche
| Name | AYTU BIOPHARMA, INC |
|---|---|
| Ticker | AYTU |
| CIK | 0001385818 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Drug Manufacturers - Specialty & Generic |
| SIC | 2834 · Pharmaceutical Preparations |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 20,4 Mio. USD |
| Beta | 0,28 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-Q | 15,165,000 | -10,584,000 | -1.05 | 122,000,000 | 14,201,000 |
| 2025-09-30 | 10-Q | 13,888,000 | 1,965,000 | -0.08 | 124,988,000 | 23,171,000 |
| 2025-06-30 | 10-K | 66,382,000 | -13,562,000 | 124,177,000 | 18,966,000 | |
| 2025-03-31 | 10-Q | 18,452,000 | 3,994,000 | 0.21 | 124,201,000 | 34,898,000 |
| 2024-12-31 | 10-Q | 16,221,000 | 788,000 | -0.26 | 116,227,000 | 30,765,000 |
| 2024-09-30 | 10-Q | 16,574,000 | 1,474,000 | -0.15 | 115,831,000 | 29,826,000 |
| 2024-06-30 | 10-K | 65,183,000 | -15,844,000 | 118,095,000 | 27,716,000 | |
| 2024-03-31 | 10-Q | 14,025,000 | -2,887,000 | -0.52 | 128,863,000 | 30,777,000 |
| 2023-12-31 | 10-Q | 18,748,000 | -220,000 | -0.04 | 131,249,000 | 32,853,000 |
| 2023-09-30 | 10-Q | 17,817,000 | -8,120,000 | -1.48 | 132,888,000 | 32,167,000 |
| 2023-06-30 | 10-K | 107,399,000 | -17,051,000 | -5.11 | 136,463,000 | 39,357,000 |
| 2023-03-31 | 10-Q | 22,733,000 | -7,200,000 | -1.93 | 147,216,000 | 40,912,000 |
| 2022-12-31 | 10-Q | 26,279,000 | -6,693,000 | -2.15 | 141,436,000 | 45,817,000 |
| 2022-09-30 | 10-Q | 27,655,000 | -701,000 | -0.28 | 150,000,000 | 48,348,000 |
| 2022-06-30 | 10-K | 96,669,000 | -108,779,000 | -74.01 | 137,623,000 | 44,308,000 |
| 2022-03-31 | 10-Q | 24,199,000 | -53,291,000 | -35.90 | 168,826,000 | 61,144,000 |
| 2021-12-31 | 10-Q | 23,125,000 | -11,548,000 | -8.74 | 223,824,000 | 105,536,000 |
| 2021-09-30 | 10-Q | 21,897,000 | -27,851,000 | -1.09 | 227,729,000 | 111,500,000 |
| 2021-06-30 | 10-K | 65,632,000 | -58,289,000 | -3.48 | 265,668,000 | 137,568,000 |
| 2021-03-31 | 10-Q | 13,482,000 | -25,460,000 | -1.41 | 271,556,601 | 143,150,000 |
Fondsaktivität (Vorquartalsvergleich)
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2025-06-09 | Disbrow Joshua R. | Officer, Chief Executive Officer | Open Market Purchase | 66,666 | 1.50 | 99,999.00 | +160,0% | |
| 2025-06-09 | Disbrow Jarrett | Officer, Chief Business Officer | Open Market Purchase | 16,666 | 1.50 | 24,999.00 | +40,0% |
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.